Pricing & Access· August 17, 2026 · 25 min read
Medicaid's September 10 Deadline: The Coverage Trade for GENEROUS Pricing
By Ran Chen#Medicaid#Drug Pricing#Payer Policy
Topic
Drug Pricing
WAC, ASP, NADAC, IRA negotiated prices, inflation rebates, and drug cost trends affecting access and coverage.
Approvals· August 12, 2026 · 34 min read
Gilead's BIC/LEN Single-Tablet HIV Regimen: PDUFA, Phase 3, and Access
By Ran Chen#FDA Approval#HIV#Gilead Sciences
Policy· August 12, 2026 · 38 min read
IARC Group 1 Call on HCTZ, Voriconazole, Tacrolimus: Pharma & P&T Actions
By Ran Chen#FDA#Label Warnings#Formulary Strategy
Policy· August 9, 2026 · 18 min read
340B Rebate-Model Ruling: D.C. Circuit Puts HHS in the Driver's Seat (2026)
By Ran Chen#340B#Drug Pricing#Payer Policy
People· August 6, 2026 · 12 min read
Pharma Copay Foundations by the Numbers: 2024 IRS 990 Analysis
Pricing & Access· August 3, 2026 · 15 min read
EU Pharmaceutical Procurement by the Numbers (2026): What 35,000 TED Tenders Reveal
By Ran Chen#Market Access#Generic Drugs#Drug Pricing
Policy· July 29, 2026 · 25 min read
FDA 503A Wellness-Peptide Vote (July 2026): Six Peptides and the Bulk-List Process
Pricing & Access· July 25, 2026 · 30 min read
NICE Appraisals by the Numbers (2026): 1,172 Appraisals, 85% Recommended
By Ran Chen#Market Access#Payer Policy#Drug Pricing
People· July 17, 2026 · 18 min read
CMS Open Payments 2025: $3.92B General and $9.50B Research by the Numbers
By Ran Chen#Drug Pricing#Commercial Strategy#Regulatory
Generics· July 15, 2026 · 29 min read
2026–2027 Generic Launch Scorecard: Which Patent Cliffs Are Worth Filing
By Ran Chen#Orange Book#Generic Entry#ANDA Approval